circulating miRNA

The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.

Researchers have demonstrated that they can detect more miRNAs, as well as other small RNA molecules, by sequencing these samples rather than using microarrays.

The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.

The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.

The researchers developed a qPCR test that analyzes microRNAs associated with ovarian cancer and plan to run a retrospective trial of the assay on biobanked samples.

Using multiple samples from more than 60,000 individuals at a participating hospital, the firm tracks circulating molecules over time in relation to cancer.

Researchers in the US and Ukraine built a microRNA-based classifier to categorize infants as affected or unaffected.

Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.

The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.

UK researchers have technically validated a qPCR testing method for a panel of four microRNAs with high sensitivity in diagnosing and monitoring rare tumors.

Pages

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.